Follicular Lymphoma

Oncology·MeSH: Lymphoma, Follicular

Prevalence

56.0 / 100K

Incidence

19.6 / 100K/yr

65 drugs in development·20 companies·38 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
brilinta	ASTRAZENECA PLC (AZN)

Phase 3(28)

Drug	Company
axicabtagene ciloleucel	GILEAD SCIENCES, INC. (GILD)
bendamustin	GH Research PLC (GHRS)
bendamustine	GENMAB A/S (GNMSF)
bendamustine	REGENERON PHARMACEUTICALS, INC. (REGN)
bendamustine	Genmab A/S (GMAB)
bendamustine	West Pharmaceutical Services Inc. (WST)
fludarabine phosphate	Filana Therapeutics Inc. (FLNA)
kte-c19	Kite Pharma, Inc. (KITE)
Liso-cel	BRISTOL MYERS SQUIBB CO (BMY)
lymphodepleting chemotherapy	Novartis AG (NVS)
Lymphodepleting chemotherapy	Novartis AG (NVS)
mosunetuzumab	GH Research PLC (GHRS)
Mosunetuzumab	ENANTA PHARMACEUTICALS INC (ENTA)
obinutuzumab	GENMAB A/S (GNMSF)
obinutuzumab	GH Research PLC (GHRS)
obinutuzumab	Genmab A/S (GMAB)
odronextamab	West Pharmaceutical Services Inc. (WST)
R-CHOP	ASTRAZENECA PLC (AZN)
R-CVP	ASTRAZENECA PLC (AZN)
R-CVP	Merus N.V. (MRUS)
Surovatamig	Merus N.V. (MRUS)
tisagenlecleucel	Novartis AG (NVS)
Tisagenlecleucel	Merus N.V. (MRUS)
Umbralisib	ASTRAZENECA PLC (AZN)
vincristin	GH Research PLC (GHRS)
vincristine	GENMAB A/S (GNMSF)
vincristine	West Pharmaceutical Services Inc. (WST)
vincristine	Genmab A/S (GMAB)

Phase 2(31)

Drug	Company
Acetaminophen	Merus N.V. (MRUS)
Axicabtagene Ciloleucel	Cidara Therapeutics, Inc. (CDTX)
Axicabtagene Ciloleucel	Structure Therapeutics Inc. (GPCR)
Axicabtagene Ciloleucel	PROTHENA CORP PUBLIC LTD CO (PRTA)
Axicabtagene Ciloleucel	Merus N.V. (MRUS)
Axicabtagene Ciloleucel	Filana Therapeutics Inc. (FLNA)
Axicabtagene Ciloleucel	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
Bendamustine Hydrochloride	FATE THERAPEUTICS INC (FATE)
Diphenhydramine	Cidara Therapeutics, Inc. (CDTX)
Diphenhydramine	PROTHENA CORP PUBLIC LTD CO (PRTA)
Diphenhydramine	Merus N.V. (MRUS)
Diphenhydramine	Filana Therapeutics Inc. (FLNA)
Fludarabine phosphate	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
Fludarabine phosphate	PROTHENA CORP PUBLIC LTD CO (PRTA)
Fludarabine phosphate	Cidara Therapeutics, Inc. (CDTX)
Ibrutinib	ENANTA PHARMACEUTICALS INC (ENTA)
Loncastuximab tesirine	ENANTA PHARMACEUTICALS INC (ENTA)
Obinutuzumab	Merus N.V. (MRUS)
Obinutuzumab	CYTOKINETICS INC (CYTK)
Obinutuzumab	FATE THERAPEUTICS INC (FATE)
tafasitamab	GH Research PLC (GHRS)
tazemetostat	GH Research PLC (GHRS)
Tazemetostat	FATE THERAPEUTICS INC (FATE)
tazverik	Epizyme, Inc. (EPZM)
Tisagenlecleucel	Novartis AG (NVS)
Umbralisib	Merus N.V. (MRUS)
Umbralisib	FATE THERAPEUTICS INC (FATE)
Umbralisib	Filana Therapeutics Inc. (FLNA)
Vincristine	FATE THERAPEUTICS INC (FATE)
Vincristine Sulfate	FATE THERAPEUTICS INC (FATE)
Zanubrutinib	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 1(3)

Drug	Company
Recombinant human interleukin-15	ENANTA PHARMACEUTICALS INC (ENTA)
tazemetostat	Epizyme, Inc. (EPZM)
Tazemetostat	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 4(2)

Drug	Company
Acetaminophen	Filana Therapeutics Inc. (FLNA)
Tislelizumab	ENANTA PHARMACEUTICALS INC (ENTA)

BioSniper tracks 65 drugs in development for Follicular Lymphoma across 20 companies.

There are 38 clinical trials targeting Follicular Lymphoma tracked by BioSniper.

The estimated prevalence of Follicular Lymphoma is approximately 56.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.